This response was also inhibited by the selective AKT kinase inhibitor, MK2206 (Fig. 6A), which result was in line with previous reports that support a role for AKT signaling in TGF-β-induced migration and epithelial-mesenchymal transition (EMT) of breast cancer cells [8]. This evidence concerns the gene TGFB1 and breast carcinoma.